<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00040430</url>
  </required_header>
  <id_info>
    <org_study_id>CP101</org_study_id>
    <nct_id>NCT00040430</nct_id>
  </id_info>
  <brief_title>Study of 111In-DAC as a Medical Imaging Agent for the Detection of Breast Cancer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Copharos</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Copharos</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and imaging ability of 111In-DAC when&#xD;
      used with planar and SPECT imaging for the detection of breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>111In-DAC</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Diagnostic</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients will be eligible for the study if they:&#xD;
&#xD;
          -  Are non-pregnant, non-lactating females 18 years of age or older(must agree to use an&#xD;
             appropriate and effective method of birth control during the study and for 2 weeks&#xD;
             after study)&#xD;
&#xD;
          -  Are being evaluated for a known or suspected breast tumor (must present with either a&#xD;
             mammographic abnormality 10mm or larger or a mammographically occult but palpable&#xD;
             abnormality of the breast)&#xD;
&#xD;
          -  Have been previously scheduled for biopsy or surgical excision of the known or&#xD;
             suspected tumor of the breast&#xD;
&#xD;
          -  Have signed an informed consent form&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Patients will not be eligible for this study if they:&#xD;
&#xD;
          -  Have a history or suspicion of significant allergic reaction or anaphylaxis to any of&#xD;
             the 111In-DAC components&#xD;
&#xD;
          -  Have a clinically unstable medical condition or opportunistic infection, a&#xD;
             life-threatening disease state, impaired renal or hepatic function or are&#xD;
             immunosuppressed&#xD;
&#xD;
          -  Are taking or have taken part in any investigational study within 30 days of start of&#xD;
             study&#xD;
&#xD;
          -  Have received an indium agent within 30 days of start of study&#xD;
&#xD;
          -  Are not able to remain immobile during scanning time&#xD;
&#xD;
          -  Have taken drugs that may damage the kidneys within 2 weeks of start of study&#xD;
&#xD;
          -  Have abnormal laboratory test results: hemoglobin &lt; 9.5 gms/dl, serum creatinine &gt; 1.5&#xD;
             mg/100ml, alkaline phosphatase 2X the upper limit of normal&#xD;
&#xD;
          -  Have undergone an excisional and/or needle localization biopsy within 4 days prior to&#xD;
             start of study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sutter Roseville Medical Center</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University at Buffalo</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14214-3007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2003</verification_date>
  <study_first_submitted>June 26, 2002</study_first_submitted>
  <study_first_submitted_qc>June 27, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2002</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

